keyword
MENU ▼
Read by QxMD icon Read
search

Folfox

keyword
https://www.readbyqxmd.com/read/27920498/feasibility-of-sequential-adjuvant-chemotherapy-with-a-3-month-oxaliplatin-based-regimen-followed-by-3-months-of-capecitabine-in-patients-with-stage-iii-and-high-risk-stage-ii-colorectal-cancer-jswog-c2-study
#1
Atsushi Tsuruta, Kazuki Yamashita, Hiroaki Tanioka, Akihito Tsuji, Michio Inukai, Toshiki Yamakawa, Tomoki Yamatsuji, Masanori Yoshimitsu, Kazuhiro Toyota, Taketoshi Yamano, Takeshi Nagasaka, Masazumi Okajima
BACKGROUND: Six months of oxaliplatin-based chemotherapy is the standard adjuvant chemotherapy for completely resected stage III colorectal cancer (CRC). Also, patients with stage II CRC who are considered to be at high risk of disease recurrence often receive the same adjuvant chemotherapy treatment. We prospectively investigated the extent and degree of neuropathy suffered by stage III and high-risk stage II resectable CRC patients who underwent sequential approach involving 3 months of an oxaliplatin-based regimen followed by 3 months of capecitabine...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27916064/-clinical-analysis-of-renal-dysfunction-in-59-patients-with-gynecological-malignant-tumor-during-chemotherapy
#2
N Li, X P Li, Y Wang, H Cui, J L Wang, L H Wei
Objective: To analysis the patients with gynecological malignant tumor and gynecologic malignant tumor complicated with kidney diseases appeared renal dysfunction during chemotherapy, and protect the residual renal function. Methods: A retrospective analysis of 59 patients with gynecological malignant tumor with abnormal renal function during chemotherapy in Peking University People's Hospital from May 2000 to April 2016. According to whether or not complicated with kidney diseases and renal dysfunction before chemotherapy, all cases were divided into two groups...
November 25, 2016: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/27899981/the-effect-and-clinical-efficacy-of-lienal-polypeptide-injection-combined-with-folfox-chemotherapy-regimen-in-colon-cancer-patients
#3
Juan Zhou, Guoping Niu, Yunfeng Pei, Chunping Cao, Chen Ding, Guangming Sun, Jing Guo, Yong Liu, Yang Yu
The aim was to investigate the clinical efficacy and immunomodulatory effect of lienal polypeptide injection combined with postoperative FOLFOX chemotherapy regimen in colon cancer patients. A total of 84 colon cancer patients were selected between January, 2014 and December, 2015. The selected patients were randomly divided into the observation (42 patients) and control (42 patients) groups. The observation group patients were treated with FOLFOX chemotherapy regimen combined with lienal polypeptide, whereas, the control group patients were treated with FOLFOX chemotherapeutic regimen only...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27881709/relationship-between-metformin-use-and-recurrence-and-survival-in-patients-with-resected-stage-iii-colon-cancer-receiving-adjuvant-chemotherapy-results-from-north-central-cancer-treatment-group-n0147-alliance
#4
Preet Paul Singh, Qian Shi, Nathan R Foster, Axel Grothey, Suresh G Nair, Emily Chan, Anthony F Shields, Richard M Goldberg, Sharlene Gill, Morton S Kahlenberg, Frank A Sinicrope, Daniel J Sargent, Steven R Alberts
BACKGROUND: Preclinical and epidemiological data suggest that metformin might have antineoplastic properties against colon cancer (CC). However, the effect of metformin use on patient survival in stage III CC after curative resection is unknown. The survival outcomes were comparable regardless of the duration of metformin use. PATIENTS AND METHODS: Before randomization to FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) with or without cetuximab, 1,958 patients with stage III CC enrolled in the N0147 study completed a questionnaire with information on diabetes mellitus (DM) and metformin use...
November 23, 2016: Oncologist
https://www.readbyqxmd.com/read/27858861/laparoscopic-assisted-low-anterior-resection-for-advanced-rectal-cancer-in-a-kidney-transplant-recipient-a-case-report
#5
Zenan Xia, Weijie Chen, Ru Yao, Guole Lin, Huizhong Qiu
INTRODUCTION: Development of de novo malignancy has become a major cause of late mortality in solid organ transplant recipients. Surgery is currently the most important treatment of choice for transplant patients with resectable CRC. However, conventional open surgery represents a great risk to these high-risk patients. They seem to benefit more from laparoscopic surgery, based on the favorable oncological outcome and remarkable short-term advantages of this approach. PATIENT CONCERNS: In this study, we have reported a case of a 50-year-old man who had underwent kidney transplantation for 4 years...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27857254/the-missing-piece-of-survivorship-cancer-prevention
#6
Lisa Kennedy Sheldon
The patient, R.C., finished her chemotherapy for breast cancer on June 4, 2007. At 58, she was ready for a better year, putting cancer treatment behind her and beginning her new life after cancer. In 2014, I was surprised to see R.C. on the schedule for chemotherapy education for 
FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin). Colorectal cancer had been discovered during a routine colonoscopy. When I met with her, she was obviously shaken and asked, "What happened? I thought I was done with cancer...
December 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/27857025/efficacy-of-chemotherapy-in-patients-with-unresectable-or-metastatic-pancreatic-acinar-cell-carcinoma-potentially-improved-efficacy-with-oxaliplatin-containing-regimen
#7
Changhoon Yoo, Bum Jun Kim, Kyu-Pyo Kim, Jae-Lyun Lee, Tae Won Kim, Baek-Yeol Ryoo, Heung-Moon Chang
Purpose: Pancreatic acinar cell carcinoma (ACC) is a rare cancer of the exocrine pancreas. Because of its rare incidence, the efficacy of chemotherapy in this patient population has been largely unknown. Therefore, we retrospectively analyzed the outcomes of patients with advanced pancreatic ACC who received chemotherapy. Materials and Methods: Between January 1997 and March 2015, 15 patients with unresectable or metastatic pancreatic ACC who received systemic chemotherapy were identified in Asan Medical Center, Korea...
November 9, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27857024/a-randomized-phase-ii-study-of-leucovorin-5-fluorouracil-with-or-without-oxaliplatin-lv5fu2-vs-folfox-for-curatively-resected-node-positive-esophageal-squamous-cell-carcinoma
#8
Sung Hee Lim, Young Mog Shim, Se Hoon Park, Hong Kwan Kim, Young Soo Choi, Myung-Ju Ahn, Keunchil Park, Jae Ill Zo, Jong-Mu Sun
Purpose: The optimal perioperative treatment for resectable esophageal squamous cell carcinoma (ESCC) remains controversial. We evaluated the efficacy and safety of leucovorin and 5-fluorouracil (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX) combination chemotherapies administered adjuvantly for curatively-resected, node-positive ESCC. Patients and methods Patients with pathologically node-positive esophageal cancer after curative R0 resection were enrolled and randomly assigned to receive LV5FU2 or FOLFOX biweekly for up to eight cycles...
November 9, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27857023/fgfr4-arg388-is-correlated-with-poor-survival-in-resected-colon-cancer-promoting-epithelial-to-mesenchymal-transition
#9
Sang Hee Cho, Chang Soo Hong, Hee Nam Kim, Min Ho Shin, Ka Rham Kim, Hyun Jeong Shim, Jun Eul Hwang, Woo Kyun Bae, Ik Joo Chung
Purpose: Fibroblast growth factor receptor (FGFR) 4 plays an important role in cancer progression during tumor proliferation, invasion, and metastasis. This study evaluated the prognostic role of FGFR4 polymorphism in patients with resected colon cancer, including the underlying mechanism. Materials and Methods: FGFR4 polymorphism was characterized in patients who received curative resection for stage III colon cancer. FGFR4-dependent signal pathways involving cell proliferation, invasion, and migration according to genotypes were also evaluated in transfected colon cancer cell lines...
November 9, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27856123/prognostic-impact-of-primary-tumor-location-on-clinical-outcomes-of-metastatic-colorectal-cancer-treated-with-cetuximab-plus-oxaliplatin-based-chemotherapy-a-subgroup-analysis-of-the-jaccro-cc-05-06-trials
#10
Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
INTRODUCTION: Primary tumor location is a critical prognostic factor in metastatic colorectal cancer (mCRC); however, it remains unclear whether tumor location is a predictor of the response to cetuximab treatment. It is also uncertain if BRAF mutation contributes to the impact of tumor location on survival. We assessed the prognostic impact of tumor location on clinical outcomes in mCRC patients treated with first-line cetuximab chemotherapy. PATIENTS AND METHODS: The associations of tumor location with overall survival and progression-free survival were evaluated in mCRC patients with KRAS exon 2 wild-type tumors who were enrolled onto 2 clinical trials: JACCRO CC-05 of cetuximab plus FOLFOX (n = 57, UMIN000004197) and CC-06 of cetuximab plus SOX (n = 61, UMIN000007022)...
October 6, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27853901/microsatellite-instability-was-not-associated-with-survival-in-stage-iii-colon-cancer-treated-with-adjuvant-chemotherapy-of-oxaliplatin-and-infusional-5-fluorouracil-and-leucovorin-folfox
#11
Jeong Eun Kim, Yong Sang Hong, Hwa Jung Kim, Kyu-Pyo Kim, Sun Young Kim, Seok-Byung Lim, In Ja Park, Chan Wook Kim, Yong Sik Yoon, Chang Sik Yu, Jin Cheon Kim, Ji Hun Kim, Tae Won Kim
BACKGROUND: The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear. We evaluated the association between MSI and survival in this population. METHODS: We analyzed 598 patients with curatively resected stage III colon cancer treated with adjuvant FOLFOX chemotherapy. We determined MSI status using polymerase chain reaction amplification; tumors were classified as high MSI (MSI-H, ≥2 unstable markers), low MSI (MSI-L, 1 unstable marker), or microsatellite stable (MSS, no unstable marker)...
November 16, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27845948/5-fluorouracil-degradation-rate-could-predict-toxicity-in-stages-ii-iii-colorectal-cancer-patients-undergoing-adjuvant-folfox
#12
Concetta E Onesti, Andrea Botticelli, Marco La Torre, Marina Borro, Giovanna Gentile, Adriana Romiti, Luana Lionetto, Antonella Petremolo, Mario Occhipinti, Michela Roberto, Rosa Falcone, Maurizio Simmaco, Paolo Marchetti, Federica Mazzuca
5-Fluorouracil is commonly used for gastrointestinal cancer treatment in an adjuvant setting; however, the toxicity can lead to a reduction, delay, or discontinuation of treatment. We retrospectively investigated the association between the 5-fluorouracil degradation rate (5-FUDR) and genetic polymorphisms of TSER, DPYD, and MHTFR with toxicity in colorectal cancer patients treated with adjuvant FOLFOX. Pretreatment 5-FUDR and MTHFR A1298T or C677T, TSER, and DPYD gene polymorphisms were characterized in stages II-III colorectal cancer patients...
November 11, 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27845412/a-comparative-analysis-and-guidance-for-individualized-chemotherapy-of-stage-ii-and-iii-colorectal-cancer-patients-based-on-pathological-markers
#13
Yang Han, Su Lu, Fudong Yu, Xisheng Liu, Huimin Sun, Jingtao Wang, Xingwu Zhu, Huijun Lu, Hao Yue, Jing Wang, Jun Lin, Chongzhi Zhou, Huamei Tang, Zhihai Peng
Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analyzed the outcomes of 902 patients with colorectal cancer treated with or without chemotherapy in our hospital. We found Chinese survival benefit for chemotherapy was consistent with current guidelines. Moreover, our data added to the evidence that chemotherapy might be used for elderly patients with stage II high-risk colorectal cancer...
November 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27843732/resection-of-large-metachronous-liver-metastasis-with-gastric-origin-case-report-and-review-of-the-literature
#14
REVIEW
Ionut Negoi, Alexandru Runcanu, Sorin Paun, Ruxandra Irina Negoi, Mircea Beuran
INTRODUCTION: Increasing evidence suggests that surgical resection may be offered to a subgroup of patients with liver metastasis of gastric adenocarcinoma. The aim of this case report is to illustrate the surgical resection of a single liver metachronous recurrence twelve months after a radical total gastrectomy for cancer. CASE REPORT: A 63-year-old male patient with an Eastern Cooperative Oncology Group performance status of 1 was referred to our hospital for a single, large liver metastasis, twelve months after a radical total gastrectomy and DII lymphadenectomy for upper third gastric adenocarcinoma...
October 3, 2016: Curēus
https://www.readbyqxmd.com/read/27822421/dual-specificity-phosphatase-5-is-a-novel-prognostic-indicator-for-patients-with-advanced-colorectal-cancer
#15
Xuebing Yan, Liguo Liu, Hao Li, Linsheng Huang, Mingming Yin, Cheng Pan, Huanlong Qin, Zhiming Jin
Dual specificity phosphatase 5 (DUSP5) is a negative regulator of Mitogen-activated protein kinase (MAPK) signaling pathway and has recently been identified as a tumor suppressor in several human malignancies. However, its clinical significance in colorectal cancer (CRC) remains unclear. In this study, we aimed to investigate the potential utility of DUSP5 as a novel biomarker for progression indication and chemotherapy benefit in CRC patients. Through quantitative real time-polymerase chain reaction and western blot, we determined that DUSP5 expression is dramatically lower in CRC tissues than that in matched normal tissues...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27803845/a-multi-institutional-feasibility-study-of-s-1-oxaliplatin-plus-bevacizumab-in-patients-with-advanced-metastatic-colorectal-cancer-the-hisco-02-prospective-phase-ii-study
#16
Manabu Shimomura, Katsunori Shinozaki, Takao Hinoi, Masanori Yoshimitsu, Manabu Kurayoshi, Daisuke Sumitani, Yasuyo Ishizaki, Takafumi Oshiro, Shinya Kodama, Yosuke Shimizu, Michinori Arita, Masakazu Tokunaga, Makoto Yoshida, Junko Tanaka, Hideki Ohdan
PURPOSE: FOLFOX is a standard combination chemotherapy regimen for metastatic colorectal cancer (CRC). 5-Fluorouracil (5-FU) is infused continuously through a pump for 46 h; therefore, replacement of infused 5-FU with oral S-1 would be more convenient for patients. We investigated the efficacy and safety of S-1/oxaliplatin (SOX) plus bevacizumab regimen in a community setting. METHODS: We conducted a phase II clinical study in Hiroshima, Japan. We enrolled individuals aged 20-80 years who had metastatic CRC, an Eastern Cooperative Oncology Group performance status of 0 or 1, assessable lesions, and not received previous chemotherapy...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27796125/-chemotherapeutic-treatment-of-metastatic-ovarian-cancer-for-8-years-case-report
#17
Dorottya Katalin Horváth, Judit Kósa, Ildikó Futó, András Telekes
The authors present the history of a 48-year-old woman, who developed pleural effusion, abdominal pain and ascites due to an advanced ovarian cancer. She underwent hysterectomy and bilateral adnexectomy in 2006, and histology revealed FIGO IIIB papillary adenocarcinoma. After surgery the patient recieved the standard, 6 cycle taxol-carboplatin therapy. Taxol-carboplatin therapy was reinitiated because of retroperitoneal lymph node metastases in 2008, but soon the therapy had to be changed because of progression...
October 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27788488/serum-exosomal-mir-4772-3p-is-a-predictor-of-tumor-recurrence-in-stage-ii-and-iii-colon-cancer
#18
Chang Liu, Cathy Eng, Jianjun Shen, Yue Lu, Takata Yoko, Amir Mehdizadeh, George J Chang, Miguel A Rodriguez-Bigas, Yanan Li, Ping Chang, Yixiang Mao, Manal M Hassan, Fangyu Wang, Donghui Li
PURPOSE: The study was aimed to evaluate the prognostic or predictive value of serum exosomal microRNAs (miRNAs) for tumor recurrence and response to adjuvant therapy in stage II and stage III colon cancer. RESULTS: 145 differentially expressed mature miRNAs were identified (P<0.05) and 10 top hits were carried forward in validation test. MiR-4772-3p was significantly under-expressed in 27 patients with recurrence compared to in 57 patients without recurrence (P=0...
October 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27780749/efficacy-tolerability-and-biomarker-analyses-of-once-every-2-weeks-cetuximab-plus-first-line-folfox-or-folfiri-in-patients-with-kras-or-all-ras-wild-type-metastatic-colorectal-cancer-the-phase-2-apec-study
#19
Ann-Lii Cheng, Gerardo Cornelio, Lin Shen, Timothy Price, Tsai-Sheng Yang, Ik Joo Chung, Guang-Hai Dai, Jen-Kou Lin, Atul Sharma, Kun-Huei Yeh, Brigette Ma, Adel Zaatar, Zhongzhen Guan, Nehal Masood, Vichien Srimuninnimit, Thomas Yau, Peter Gibbs, Xiuwen Wang, Dinesh Chandra Doval, Seung-Taek Oh, Byoung Yong Shim, Charity Gorospe, Hwei-Ming Wang, Ekaphop Sirachainan, Andrew Hill, Kwang Wook Suh, Frank Beier, Sudipto Chatterjee, Robert Lim
BACKGROUND: In patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC), outcomes with first-line chemotherapies are improved by adding weekly cetuximab. The APEC study investigated first-line once-every-2-weeks cetuximab plus chemotherapy for patients with KRAS wt mCRC; additional biomarker subgroups were also analyzed. PATIENTS AND METHODS: APEC was a nonrandomized phase 2 trial conducted in the Asia-Pacific region. Patients (n = 289) received once-every-2-weeks cetuximab with investigator's choice of chemotherapy (FOLFOX or FOLFIRI)...
September 7, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27765757/ramucirumab-combined-with-folfox-as-front-line-therapy-for-advanced-esophageal-gastroesophageal-junction-or-gastric-adenocarcinoma-a-randomized-double-blind-multicenter-phase-ii-trial
#20
H H Yoon, J C Bendell, F S Braiteh, I Firdaus, P A Philip, A L Cohn, N Lewis, D M Anderson, E Arrowsmith, J D Schwartz, L Gao, Y Hsu, Y Xu, D Ferry, S R Alberts, Z A Wainberg
BACKGROUND: We report the first randomized, Phase II trial of ramucirumab, an anti-vascular endothelial growth factor receptor-2 monoclonal antibody, as front-line therapy in patients with advanced adenocarcinoma of the esophagus or gastric/gastroesophageal junction (GEJ). PATIENTS AND METHODS: Patients from the USA with advanced esophageal, gastric, or GEJ adenocarcinoma randomly received (1:1) mFOLFOX6 plus ramucirumab (8 mg/kg) or mFOLFOX6 plus placebo every 2 weeks...
October 20, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
2273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"